B. Nguyen

发表

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

C. Katlama, J. Gatell, A. Lazzarin, 2007, The Lancet.

Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection

B. Clotet, D. Cooper, R. Steigbigel, 2015, Antiviral therapy.

Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women

M. Hughes, L. Mofenson, P. Deutsch, 2006, Antimicrobial Agents and Chemotherapy.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

B. Clotet, C. Katlama, J. Gatell, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

C. Katlama, M. Saag, J. Rockstroh, 2015, The lancet. HIV.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

T. Hassanein, S. Pol, D. Nelson, 2015, The Lancet.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

P. Sax, K. Squires, P. Cahn, 2018, Journal of acquired immune deficiency syndromes.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

A. Lazzarin, M. Saag, J. Rockstroh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

C. Crumpacker, C. Kovacs, R. Danovich, 2009, Journal of acquired immune deficiency syndromes.

Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.

E. Asante-Appiah, R. Flisiak, B. Nguyen, 2016, Journal of hepatology.

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis

V. de Lédinghen, E. Asante-Appiah, T. Asselah, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, J. Wagner, B. Nguyen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin‐like growth factor in HIV‐infected patients

D. Longo, M. Baseler, D. Venzon, 1998, AIDS.

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

M. Kozal, R. Leavitt, F. Raffi, 2012, HIV clinical trials.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

B. Clotet, J. Gatell, D. Cooper, 2013, The Lancet. Infectious diseases.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

K. Mounzer, K. Squires, L. Bekker, 2013, AIDS research and human retroviruses.

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)

H. Teppler, E. Gotuzzo, B. Nguyen, 2012, Journal of acquired immune deficiency syndromes.

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

A. Lazzarin, M. Saag, J. Rockstroh, 2012, HIV Clinical Trials.

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

J. Eron, M. Rizk, J. Zhao, 2012, Antimicrobial Agents and Chemotherapy.

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

Jinrong Zhao, J. Rockstroh, R. Leavitt, 2011, AIDS.

Long-Term Safety from the Raltegravir Clinical Development Program

R. Leavitt, H. Teppler, F. Lievano, 2011, Current HIV research.

Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season

L. Godderis, B. Nguyen, G. Dos Santos, 2019, Drug Safety.

A case of hyperdynamic shock caused by trimethoprim-sulfamethoxazole in which no tumor necrosis factor or features of anaphylaxis were detected.

R. Walker, R. Cunnion, B. Nguyen, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

C. Kovacs, D. Cooper, R. Steigbigel, 2006, Journal of acquired immune deficiency syndromes.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Adriano Lazzarin, Edwin DeJesus, Peter Sklar, 2009, The Lancet.

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

D. Hazuda, D. Cooper, H. Teppler, 2007, AIDS.

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

C. Crumpacker, C. Kovacs, H. Teppler, 2007, Journal of acquired immune deficiency syndromes.

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

S. Steinberg, H. Mitsuya, O. Brawley, 1994, The Journal of infectious diseases.

Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.

D. Venzon, H. Mitsuya, S. Broder, 1995, The Journal of infectious diseases.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

C. Katlama, P. Sax, Y. Yazdanpanah, 2017, The lancet. HIV.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK

Y. Yazdanpanah, M. Saag, J. Rockstroh, 2013, Journal of acquired immune deficiency syndromes.

A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.

D. Venzon, S. Broder, O. Brawley, 1993, The Journal of infectious diseases.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, C. Orkin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

P. Sax, K. Squires, P. Cahn, 2018, The lancet. HIV.

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

D. Nickle, B. Conway, F. Altice, 2016, Annals of internal medicine.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

D. Cooper, M. Youle, R. Leavitt, 2010, The Lancet.

Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium

D. Hazuda, R. Leavitt, H. Teppler, 2011, Annals of the New York Academy of Sciences.

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

William M. Lee, M. Colombo, R. Talwani, 2017, Hepatology.

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine

J. Gallant, D. Mehrotra, D. Haas, 2000, AIDS.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

L. Markson, J. Mellors, E. Dasbach, 1999, AIDS research and human retroviruses.

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.

S. Steinberg, H. Mitsuya, B. Nguyen, 1999, Antiviral research.

GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

K. Reddy, S. Zeuzem, J. Butterton, 2015, Annals of Internal Medicine.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

A. Lazzarin, Jinrong Zhao, R. Leavitt, 2010, Journal of acquired immune deficiency syndromes.

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

S. Pol, D. Nelson, M. Silva, 2017, The lancet. Gastroenterology & hepatology.

Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus

J. Rockstroh, R. Leavitt, H. Teppler, 2010 .

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

B. Conway, F. Altice, G. Dore, 2016 .

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.

S. Steinberg, R. Nelson, C. Mackall, 2001, The Journal of infectious diseases.

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study

C. Katlama, J. Gatell, A. Lazzarin, 2010, Journal of acquired immune deficiency syndromes.

Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials

R. Talwani, V. Luketic, B. Nguyen, 2018, The American Journal of Gastroenterology.

Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.

S. Hammer, A. Wu, J. Heyse, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience

S. Hammer, K. Squires, M. Fischl, 2008, HIV clinical trials.

Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection

R. Talwani, I. Sheen, J. George, 2018, Hepatology communications.

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

S. Klopfer, B. Nguyen, E. Barr, 2017, Hepatology communications.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

A. Lazzarin, R. Leavitt, R. Pollard, 2009, The Lancet.

GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

K. Reddy, S. Zeuzem, J. Butterton, 2015, Annals of Internal Medicine.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, B. Nguyen, M. Iwamoto, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

S. Pol, D. Nelson, M. Silva, 2017, The lancet. Gastroenterology & hepatology.

The 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016.

Kinh Nguyen Van, R. Talwani, I. Sheen, 2016, Hepatology.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

A. Lazzarin, M. Saag, J. Rockstroh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.